Colistin Therapy, Survival and Renal Replacement Therapy in Burn Patients: A 10-Year Single-Center Cohort Study.
CRRT
MDRGN infection
acute kidney injury
burns
clinical outcome
colistin
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
accepted:
24
03
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Colistin is still a therapeutic cornerstone against multidrug-resistant gram-negative bacteria (MDRGN), mostly when other antibiotics do not gain adequate activity on these strains. In the present study, we evaluated in a cohort of burn patients the relationship between colistin therapy, survival and requirement of renal replacement therapy (CRRT). Retrospective study of 133 burn patients treated with iv colistimethate sodium (loading dose 9.0 × 10 Out of 133 colistin- and 35 other antibiotics-treated patients, 83 (62.4%) and 31 (88.6%) survived, and 53 (39.8%) and 3 (9.7%) required CRRT, respectively. The severity of burns, as well as CRRT requirement and mortality, was significantly higher in colistin-treated patients than in other antibiotics-treated patients. Age and TBSA% were the significant predictors of mortality. Out of 83 colistin-treated survivors, 19 (22.9%) required CRRT (9 before and 10 after the start of colistin), and 64 (77.1%) had a normal renal function. No difference about the colistin dose and baseline characteristics, but the revised Baux score was found between the 9 patients requiring CRRT before the colistin course and the 10 patients after. Similarly, among the 64 patients not undergoing CRRT, no difference was found between the patients treated with the cumulative dose of colistin <99.0 × 10 Colistin therapy was associated with more severe burns, mortality, and CRRT requirement. A short course therapy, at appropriate cumulative dosage, can lead to clinical success without a significant association with severe renal impairment.
Identifiants
pubmed: 35651672
doi: 10.2147/IJGM.S357427
pii: 357427
pmc: PMC9150021
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5211-5221Informations de copyright
© 2022 Mariano et al.
Déclaration de conflit d'intérêts
The authors declare that they have no financial and/or non-financial competing interests.
Références
Clin Microbiol Infect. 2021 Jan 6;:
pubmed: 33359542
Clin J Am Soc Nephrol. 2018 Apr 6;13(4):542-550
pubmed: 29545383
Int J Antimicrob Agents. 2020 Mar;55(3):105889
pubmed: 31923573
Burns. 2020 Feb;46(1):190-198
pubmed: 31787473
Curr Infect Dis Rep. 2019 Nov 16;21(12):46
pubmed: 31734740
J Clin Med. 2021 Dec 09;10(24):
pubmed: 34945056
Int J Nephrol Renovasc Dis. 2013 Jun 07;6:107-11
pubmed: 23776390
Burns Trauma. 2020 Oct 22;8:tkaa027
pubmed: 33123606
Burns Trauma. 2021 Feb 04;9:tkaa047
pubmed: 33654698
J Am Coll Surg. 2006 Oct;203(4):546-50
pubmed: 17000400
Antimicrob Agents Chemother. 2015 Nov 02;60(1):431-6
pubmed: 26525802
J Burn Care Res. 2017 Sep/Oct;38(5):271-282
pubmed: 27617407
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
J Burn Care Res. 2017 May/Jun;38(3):187-193
pubmed: 27775983
J Burn Care Res. 2012 May-Jun;33(3):379-85
pubmed: 22079911
Antibiotics (Basel). 2020 Apr 20;9(4):
pubmed: 32326058
Crit Care Med. 2015 Jun;43(6):1187-93
pubmed: 25756417
J Antimicrob Chemother. 2017 Jan;72(1):319-321
pubmed: 27591295
J Chemother. 2021 Feb;33(1):62-66
pubmed: 32588768
Antibiotics (Basel). 2019 Mar 14;8(1):
pubmed: 30875778
Microorganisms. 2020 Feb 20;8(2):
pubmed: 32093299
Burns. 2010 Mar;36(2):205-11
pubmed: 19836141
Pharmaceutics. 2021 Jan 26;13(2):
pubmed: 33530483
J Glob Antimicrob Resist. 2020 Mar;20:43-49
pubmed: 31207379
Burns. 2019 Nov;45(7):1495-1508
pubmed: 31351820
Int J Infect Dis. 2019 Feb;79:179-184
pubmed: 30529108
Am J Infect Control. 2019 Apr;47(4):435-438
pubmed: 30503627
Pharmacotherapy. 2019 Jan;39(1):10-39
pubmed: 30710469
J Surg Res. 2020 Jul;251:53-62
pubmed: 32113038
Ther Drug Monit. 2014 Apr;36(2):182-91
pubmed: 24216535
Ren Fail. 2020 Nov;42(1):704-709
pubmed: 32703065
PeerJ. 2020 Sep 29;8:e9984
pubmed: 33072437
Intensive Care Med. 2017 Jun;43(6):730-749
pubmed: 28577069
J Nephrol. 2015 Oct;28(5):623-31
pubmed: 25249467
Antibiotics (Basel). 2021 Apr 22;10(5):
pubmed: 33922151
World J Crit Care Med. 2016 May 04;5(2):111-20
pubmed: 27152254
Eur J Clin Pharmacol. 2015 Jul;71(7):801-10
pubmed: 26008213
J Nephrol. 2015 Apr;28(2):151-64
pubmed: 25585821
Burns. 2010 Jun;36(4):522-7
pubmed: 19864072
Kidney Int. 2020 Aug;98(2):294-309
pubmed: 32709292
J Trauma Acute Care Surg. 2014 Mar;76(3):840-5
pubmed: 24553558
Burns. 2017 Sep;43(6):1244-1249
pubmed: 28410932